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Interleukin-2: Biology, Design
and Application
Natalia Arenas-Ramirez,1,2 Janine Woytschak,1,2 and
Onur Boyman1,*
Interleukin-2 (IL-2) exerts crucial functions during immune homeostasis via its
effects on regulatory T (Treg) cells, and the optimizing and ﬁne-tuning of effector
lymphocyte responses. Thus, somewhat paradoxically, low doses of recombi-
nant IL-2 have been used for Treg cell-based immunosuppressive strategies
against immune pathologies, while high-dose IL-2 has shown some success in
stimulating anti-tumor immune responses. Recent studies of the functional,
biophysical and structural characteristics of IL-2 have led to the generation
of IL-2 formulations, including IL-2/mAb complexes and IL-2 variants (muteins)
that selectively enhance IL-2's immune stimulatory versus inhibitory properties.
Here, we review these ﬁndings, placing new mechanistic insights into improved
next-generation IL-2 formulations within the broader context of IL-2 biology.
We conclude by integrating these ﬁndings into a framework for understanding
IL-2-mediated selective immune modulation.
Introduction
Discovered, isolated, and cloned between 1976 and 1983, IL-2 was the ﬁrst immunotherapy
demonstrating clinical efﬁcacy in metastatic cancer [1–5]. Despite these promising data, IL-2
immunotherapy has not been widely adopted for various reasons, including its difﬁcult adminis-
tration due to its short in vivo half-life (T½), its toxic adverse effects when administered at high doses
(as needed for antitumor immunotherapy), and its ability to stimulate both cytotoxic effector T cells
and regulatory T (Treg) cells [6]. While activation of Treg cells is an unwanted effect in anticancer IL-2
immunotherapy, as Treg cells can dampen effector T cell responses against tumor antigens, the
property of IL-2 – even at low doses – to stimulate Treg cells could be harnessed for the treatment of
Treg cell-deﬁcient autoimmune and chronic inﬂammatory disorders [7].
The past 10 years rekindled an interest in IL-2 immunotherapy, which came from structural and
biophysical insights into the complex formed by IL-2 with its IL-2 receptor (IL-2R) subunits [8]
and the ﬁnding that IL-2 could be modiﬁed to selectively stimulate either cytotoxic effector T cells
or Treg cells [9]; these studies have led to the generation of IL-2 formulations with improved and
selective immune stimulatory capacities [10]. Furthermore, clinical trials using low-dose IL-2
have demonstrated IL-2's potential in expanding Treg cells and modulating immune pathologies
[11,12]. Four recent publications exemplify this development and have motivated this review, in
that they provide structural insight into the selective IL-2-mediated modulation of immune
responses using IL-2/monoclonal antibody (mAb) complexes [13], highlight the possibility of
using IL-2 muteins to antagonize, rather than stimulate, IL-2R-induced signals [14], and report
novel data on the clinical use of low-dose IL-2 therapy in organ-speciﬁc and systemic autoim-
mune disease [15,16].
To place these ﬁndings in context, we begin by providing an introduction into the biology of IL-2
and its receptors, followed by a discussion of IL-2/mAb complexes and IL-2 muteins, and end by
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summarizing the key concepts arising from these studies as well as indicating gaps in our current
understanding.
The Biology of IL-2
IL-2 is a 15.5–16-kDa, four-/-helix-bundle cytokine (Figure 1) that exerts its actions via binding
to various IL-2Rs, notably monomeric, dimeric, and trimeric IL-2Rs [6,17,18]. Monomeric IL-
2Rs, comprising IL-2R/ (CD25), are usually cell membrane associated but also exist in soluble
form and bind IL-2 with a low Kd of 108 M. Interaction of IL-2 with CD25 alone does not
induce a signal [19]; hence, isolated membrane-bound or soluble CD25 molecules might serve
as scavenger or decoy receptors for IL-2 [6,20]. Conversely, both dimeric and trimeric IL-2Rs
lead to a downstream signal on binding to IL-2. Dimeric IL-2Rs comprise IL-2Rb (CD122) and IL-
2Rg [better known as common g-chain (gc) or CD132], whereas trimeric IL-2Rs comprise CD25,
CD122, and gc (Figure 2). Of note, CD122 is also part of IL-15R, whereas gc is shared by IL-2, IL-
4, IL-7, IL-9, IL-15, and IL-21 [18]. Considering only IL-2Rs with signaling capacity, dimeric IL-
2Rs can be referred to as low-afﬁnity (Kd 109 M) and trimeric IL-2Rs as high-afﬁnity (Kd
1011 M) IL-2Rs [19]. On a molecular level, a single trimeric IL-2R binds IL-2 with roughly 10–
100-fold higher afﬁnity than a single dimeric IL-2R, illustrating that one function of CD25 is to
improve IL-2 binding to the dimeric IL-2R. Association of IL-2 with IL-2R causes internalization of
the quaternary complex, on which IL-2, CD122, and gc become degraded in vesicles, whereas
CD25 is recycled via endosomes to the cell surface [21]. Notably, internalization of IL-2 has been
suggested to depend on the cytoplasmic part of gc, suggesting that gc-mediated signaling is
involved [22].
On triggering of IL-2R, signal transduction occurs via three major pathways, involving: (i) Janus
kinase (JAK)–signal transducer and activator of transcription (STAT); (ii) phosphoinositide 3-
kinase (PI3K)–AKT; and (iii) mitogen-activated protein kinase (MAPK) [6,18] (see Figure 2 for
more details). Moreover, IL-2 signaling activates the transcription factor B lymphocyte-induced
maturation protein 1 (Blimp1), encoded by Prdm1, which serves as a negative feedback loop by
repressing IL-2 production.
Several immune cells have been shown to secrete IL-2 when activated, including T cell receptor
(TCR) /b+ and TCRgd+ T cells, natural killer (NK) cells, NKT cells, dendritic cells (DCs), and mast
cells [6]. At resting conditions, CD4+ helper T (Th) cells are the main source of the constant but
low levels of IL-2. On immune activation, IL-2 production rapidly rises. Low IL-2 secretion by
activated DCs has been suggested to provide an early IL-2 source [23], thereby supporting T cell
stimulation. In parallel, activated T cells, including CD4+ and CD8+ T cells, start secreting large
amounts of IL-2 for their own (autocrine) use and to stimulate in a paracrine fashion neighboring
IL-2R+ cells [6,17,18]. Interestingly, Treg cells are unable to produce IL-2, even on stimulation,
unless they constitute peripherally derived (‘induced’) Treg cells redifferentiating to Th cells [24].
IL-2 production by activated T cells is transient and transcriptionally regulated, including
silencing by Blimp1 and Aiolos (encoded by Ikzf3) [18]. Moreover, negative feedback appears
to also exist on the cellular level involving IL-2-producing CD4+ T and IL-2-consuming Treg cells
[25]. Such regulation mechanisms might be key in preventing T cell overstimulation by persistent
IL-2 signals in conjunction with repetitive TCR stimulation by antigen (including self- and tumor
antigens), which can lead to T cell exhaustion or Fas (CD95)-mediated activation-induced cell
death [26,27].
In terms of IL-2 responsiveness, in vitro activated human T cells have been reported to carry
about 2000 high-afﬁnity and 11 000 low-afﬁnity IL-2Rs per cell [4,28]. Dimeric IL-2Rs are
expressed at high levels on antigen-experienced (memory) CD8+ T cells and NK cells, whereas
low to intermediate levels of dimeric IL-2Rs are found on memory CD4+ and naive T cells [6]. On
TCR stimulation, T cells transiently upregulate CD25, thus expressing now trimeric IL-2Rs. In
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addition to recently activated T cells, high levels of trimeric IL-2Rs (precisely, high CD25 levels
plus intermediate levels of dimeric IL-2Rs) are found constitutively on thymus-derived (‘natural’)
CD4+ forkhead box p3 (Foxp3)+ Treg cells [29], whereas type 2 innate lymphoid cells (ILC2) and
certain nonimmune cells (such as pulmonary endothelial cells) have been reported to carry low to
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Figure 1. Sequence and Structure of IL-2 in Association with its Receptor Subunits. (A) Amino acid sequence of
IL-2, indicating amino acids that interact with IL-2 receptor (IL-2R) subunits, including IL-2R/ (CD25; pink), IL-2Rb (CD122;
orange), and common g-chain (gc, CD132; purple). Human IL-2 comprises 133 amino acids and weighs 15.5 kDa; mouse
IL-2 measures 149 amino acids and has 16 kDa molecular mass. Human and mouse IL-2 show 57% sequence homology,
yet human IL-2 can efﬁciently stimulate mouse IL-2Rs whereas mouse IL-2 is rather inefﬁcient in binding to human IL-2Rs.
(B) Human IL-2 (light blue) and its epitopes for CD25 (pink), CD122 (orange), and gc (purple) (accession code PDB: 1M47
[82]). (C) 3D structure of the quaternary IL-2–IL-2R complex, comprising IL-2 (light blue), CD25 (pink), CD122 (orange), and
gc (purple) (accession code PDB: 2B5I [8]).
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Figure 2. IL-2 Receptor (IL-2R) Binding and Signaling. Cartoon of IL-2 interacting with its receptor subunits, including
IL-2R/ (CD25), IL-2Rb (CD122), and the common g-chain (gc, CD132), as well as signaling pathways following the
interaction of IL-2 with various IL-2R subunits. Binding of IL-2 to CD122 and gc causes heterodimerization of the cytoplasmic
tails of these receptor subunits and activation of Janus kinase 1 (JAK1) and JAK3 (associated with CD122 and gc,
respectively) [18]. Activated JAK1 and JAK3 exert kinase activity on key tyrosine (Y) residues of CD122, which subsequently
allows recruitment of the adaptor protein SHC and of STAT1, STAT3, and STAT5 (including STAT5A and STAT5B).
Phosphorylated STAT5A and STAT5B then oligomerize forming STAT5 dimers and tetramers before undergoing nuclear
translocation, where they bind to key target genes responsible for cell activation, differentiation, and proliferation. SHC in
turn serves as a platform for activating the Ras–Raf–MEK–ERK mitogen-activated protein kinase (MAPK) pathway.
Additionally, IL-2R triggering activates the phosphoinositide 3-kinase (PI3K)–AKT–mammalian target of rapamycin
(mTOR)–p70 S6 kinase pathway.
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very low levels of trimeric IL-2Rs [30,31]. Furthermore, activated mouse and human B cells
express functional trimeric IL-2Rs and proliferate in vitro on stimulation with human IL-2 (hIL-2)
[32,33]. Interestingly, DCs have been reported to express CD25 and to use CD25 to present IL-2
in trans to T cells expressing dimeric IL-2Rs [23,34] (Figure 2). Whether DCs carry CD122 is
controversial, and stronger evidence suggests that DCs do not express CD122 under steady-
state conditions [6,34].
The low but constant IL-2 production during resting conditions serves primarily for the devel-
opment and homeostatic survival of Treg cells, which in turn maintain peripheral immune
tolerance by dampening (autoreactive) effector T cells [15,17,35]. Treg cell dependence on
IL-2 signaling is maybe best illustrated in IL-2- or IL-2R subunit (CD25 or CD122)-deﬁcient
animals and patients, which all lack Foxp3+ Treg cells and develop systemic autoimmunity and
inﬂammatory bowel disease. In IL-2R-deﬁcient mice, this pathology can be prevented by
adoptive transfer of wild-type Treg cells [36,37]. Following immune stimulation, local IL-2
concentrations increase several-fold, especially in secondary lymphoid organs, causing prolif-
eration of NK cells as well as memory and recently activated effector T cells. Timed IL-2 signals
are also required for optimal primary and secondary CD8+ T cell responses [6,38,39] as well as
for effector-to-memory transition in CD4+ T cells [40]. Furthermore, IL-2 in concert with polarizing
cytokines (pcs) (in parentheses) facilitates differentiation of naive Th cells to interferon-g-produc-
ing Th1 (pc: IL-12), IL-4-, IL-5-, IL-9-, and IL-13-secreting Th2 (pc: IL-4), and peripherally derived
(‘induced’) Treg [pc: transforming growth factor-b (TGF-b)] cells, while conversion of Th cells to
IL-17A-, IL-17F-, and IL-22-producing Th17 (pcs: IL-6 and TGF-b) and follicular Th (pcs: IL-6
and IL-21) cells is curtailed by IL-2 signaling [6,18].
According to the current view, low doses of IL-2 [i.e., 1 500 000–3 000 000 international units
(IU) once daily in humans or 15 000–30 000 IU or lower once daily in mice] preferentially stimulate
Treg cells, although some effector T and NK cells might become activated as well [7]. Low-dose
IL-2 might thus be suitable for the treatment of autoimmune and chronic inﬂammatory diseases
such as systemic lupus erythematosus (SLE), type 1 diabetes, and cryoglobulinemic vasculitis
[11,15,16,41,42], as well as graft rejection and chronic graft-versus-host disease [12,43], as
these conditions have been reported to often feature lower IL-2 signaling and a relative Treg to
effector T cell deﬁciency [7]. In line with this, a recent study showed, in patients with SLE, a
relative reduction of Treg to effector T cells, with Treg cells displaying lower CD25 levels;
moreover, cultured (but unstimulated) peripheral blood mononuclear cells and CD4+ T cells
from SLE patients showed deﬁcient ex vivo IL-2 production [16]. Administration of a 5-day
course of low-dose IL-2 to ﬁve SLE patients led to preferential stimulation of Treg over effector T
cells, thus restoring Treg to effector T cell balance [16], as also observed in other pathologies
[7,43]. According to a recent publication on human Treg cells from healthy controls and patients
with type 1 diabetes, Treg cells seem to be especially poised to sense low concentrations of IL-2,
as assessed by measuring phosphorylated STAT5, in part due to their high expression of CD25
and gc as well as their further transcriptional upregulation of CD25 and Foxp3 rapidly on IL-2;
conversely, about tenfold higher IL-2 concentrations were needed to induce STAT5 phosphor-
ylation in other lymphocytes, with memory CD4+ T cells and CD56high NK cells being the next-
most-sensitive subsets, followed by naive CD4+ and memory CD8+ T cells and naive CD8+ T and
CD56low NK cells [15].
Conversely, high-dose IL-2 (i.e., 600 000–720 000 IU/kg body weight three times daily for up to
14 doses per cycle in humans or 100 000 IU or higher once or twice daily in mice) has been used
for immunotherapy against metastatic cancer [5] as high doses of IL-2 stimulate antitumor
cytotoxic lymphocytes, including effector T and NK cells, presumably, once trimeric IL-2Rs on
Treg cells have been saturated with IL-2. High-dose IL-2 treatment leads to 15–19% objective
clinical response, including 7–9% complete response, in patients with metastatic melanoma or
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metastatic renal cell carcinoma [5]. Other diseases where IL-2 immunotherapy has been tried
comprise inherited and acquired immune deﬁciencies, the latter including chronic HIV infection,
and other viral infections [44–46]. As an alternative to low-dose versus high-dose IL-2, various
selective IL-2 formulations have been generated, including IL-2/mAb complexes and mutant IL-
2 molecules (IL-2 muteins), which are discussed in the next sections.
IL-2/mAb Complexes
IL-2/mAb complexes (also termed IL-2 complexes or IL-2/anti-IL-2 mAb complexes) consist of
IL-2 plus a particular anti-IL-2 mAb. The anti-IL-2 mAb can bind to and potentiate endogenous
or recombinant IL-2 [6,9].
Two functionally distinct IL-2/mAb complexes are distinguished [6,9,47]. Use of the anti-mouse
IL-2 (mIL-2) mAb S4B6 (i.e., mAb clone S4B6-1 or other S4B6-like mAbs, including JES6-5H4
for mIL-2 and MAB602 for hIL-2) generates IL-2/mAb complexes that preferentially stimulate
cells expressing high levels of dimeric IL-2Rs, most notably memory (and memory-phenotype)
CD8+ T cells and NK cells. Conversely, IL-2/mAb complexes comprising IL-2 plus the anti-mIL-2
mAb JES6-1 (i.e., mAb clone JES6-1A12 or anti-hIL-2 mAb 5344) selectively activate cells
carrying high levels of CD25 in addition to CD122 and gc. For example, ﬁve to seven daily
injections of IL-2/S4B6 complexes (using 15 000 IU IL-2) expand memory CD8+ T cells and NK
cells by 20–40-fold, while on such treatment CD25+ Foxp3+ Treg cell counts increase by two- to
ﬁvefold only [9,31,47]. This selectivity correlates with CD122 expression on memory CD8+ T and
NK cells (both CD122high) versus Treg cells (expressing intermediate levels of CD122). Moreover,
by avoiding contact with CD25+ endothelial cells and by reducing the IL-2 dose needed for
clinical efﬁcacy, IL-2/S4B6 complexes exert less endothelial cell damage and vascular leak
syndrome (VLS) in the lungs and liver of treated animals [31] (see also the section on IL-2
muteins). Given these properties, IL-2/S4B6 complexes could be used therapeutically in
metastatic malignancies and chronic viral infection. In support of this notion, several groups
have reported favorable results using IL-2/S4B6 complexes either as a monotherapy or in
combination with another agent (such as Toll-like receptor ligand, agonist anti-OX40 mAb, or
peptide vaccine) in various cancer models, including B16 melanoma, Lewis lung carcinoma,
MC38 colon carcinoma, MCA-205 sarcoma, and TRAMP-C1 prostate carcinoma [31,48–53].
Moreover, IL-2/S4B6 complexes have shown efﬁcacy in models of acute and chronic infection
[54,55].
For IL-2/JES6-1 complexes, a short course of three to seven daily injections of these complexes
increases CD25+ Foxp3+ Treg cell numbers by 7–15-fold, while CD8+ T and NK cells are not
signiﬁcantly affected by IL-2/JES6-1 complexes [9,47,56]. IL-2/JES6-1 complexes are also
stimulatory for ILC2 that express trimeric IL-2Rs, which contributes to IL-5 production and
eosinophilia [30,57]. IL-2/JES6-1 complexes have shown promising results in the prevention of
pancreatic [56] and skin [58] allograft rejection as well as in the treatment of several autoimmune
and inﬂammatory diseases in mice, including type 1 diabetes in nonobese diabetic mice [59],
experimental autoimmune encephalomyelitis (a model of multiple sclerosis) [56], experimental
myasthenia [60], collagen-induced arthritis [61], dextran sodium sulfate-induced acute colitis
[13], and T cell-mediated allergic airway disease [62]. Interestingly, administration of IL-2/JES6-1
complexes also improved the pathology of some metabolic, cardiovascular, and degenerative
disorders, such as murine obesity-induced inﬂammation and insulin resistance (‘type 2 diabe-
tes’) [63], atherosclerosis in high-fat diet-fed apolipoprotein E-deﬁcient animals [64], and the mdx
mouse model of Duchenne muscular dystrophy [65], that feature inﬂammatory inﬁltrates and are
thus amenable to suppression by CD25+ Foxp3+ Treg cells.
Mechanistically, IL-2/mAb complexes are characterized, compared with IL-2, by increased in
vivo potency and selectivity toward CD122high versus CD25high cells. Regarding their enhanced
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potency, IL-2/mAb complexes display an increased biological T½ compared with IL-2 [47].
Unmodiﬁed IL-2 is rather short lived on intravenous injection (T½ 3–5 min in mice and 7–10 min
in humans) due to its rapid clearance in the kidneys, probably by degradation, followed by
delayed clearance [66–68]. The association of IL-2 with larger molecules, including serum
albumin, liposomes, and irrelevant mAbs or mAb fragments (i.e., unrelated mAbs speciﬁc for
antigens other than IL-2), increases the lifespan of IL-2 [69]. Similarly, association of IL-2 with
S4B6 or JES6-1 increases IL-2 T½ by about 10–20-fold [47,70]. This T½ increase depends on
neonatal Fc receptors and is crucial for the activity of IL-2/JES6-1 complexes and, to a lesser
extent, IL-2/S4B6 complexes; contrarily, Fc receptors for IgG (FcRg) do not appear to play
a signiﬁcant role in the bioactivity of IL-2/mAb complexes [47,70]. Nevertheless, similar to
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Figure 3. 3D Structure of IL-2/mAb
Complexes. (A,B) The complexes
formed by mouse IL-2 with Fab fragments
of anti-mouse IL-2 monoclonal antibody
(A) S4B6 (clone S4B6-1; accession code
PDB: 4YUE [13]) or (B) JES6-1 (clone
JES6-1A12; accession code PDB:
4YQX [13]) overlaying the human IL-2–
IL-2R complex (accession code PDB:
2B5I [8]).
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CD25-mediated trans-presentation of IL-2 by DCs to T cells [34], IL-2/mAb complexes might
bind to FcRgs on DCs and become presented in trans to T cells, although this has not been
formally proven. Of note, the anti-IL-2 mAbs belong to various IgG subclasses – with S4B6 being
rat IgG2a, JES6-5H4 rat IgG2b, JES6-1 rat IgG1, MAB602 mouse IgG2a, and 5344 mouse
IgG1 [9,47] – suggesting that, for these mAbs, subclass plays a subordinate role.
Another mechanism for the superagonistic in vivo activity of IL-2/mAb complexes could be
enhanced IL-2R signaling due to crosslinking of two dimeric IL-2Rs by an IL-2 complex,
structural changes in IL-2 on mAb binding, or prolonged interaction of IL-2 with its receptor.
IL-2R crosslinking has so far not been formally disproved. Yet, compared with IL-2, testing of IL-
2/S4B6 complexes in vitro on CD25 YT-1 human NK cells induced decreased STAT5
phosphorylation [13] and lower proliferation of wild-type and CD25/ memory-phenotype
mouse CD8+ T cells [9]. These data would rather argue against IL-2R crosslinking by IL-2/
S4B6 complexes. For IL-2/JES6-1 complexes, STAT5 phosphorylation was reduced in CD25+
YT-1 human NK cells compared with IL-2 in vitro [13], although another report using in vitro
stimulation of total mouse splenocytes suggested that, compared with IL-2, IL-2/JES6-1
complexes led to increased STAT5 phosphorylation in CD4+ T cells [71]. In line with the former
ﬁnding, activation of CD25+ murine CD8+ T cells in vitro led to about tenfold lower proliferation
with IL-2/JES6-1 complexes compared with IL-2 [9]. Conversely, in vivo IL-2/JES6-1 complexes
led to prolonged and increased phosphorylation of STAT5 in Treg cells compared with IL-2 [61].
In its simplest embodiment, a mechanistic model for the selectivity of different IL-2/mAb
complexes should explain the following observations [6,9]: (i) IL-2/mAb complexes are formed
using in vitro ‘neutralizing’ anti-IL-2 mAbs; (ii) S4B6 and JES6-1 bind to different IL-2 sites; (iii) IL-
2/S4B6 complexes mediate CD122-dependent but CD25-independent responsiveness of cells;
and (iv) stimulation of cells by IL-2/JES6-1 complexes is strictly CD25 dependent. Based on
functional in vivo and in vitro data, it has been proposed that the different functional properties of
IL-2/S4B6 and IL-2/JES6-1 complexes are a result of the mAbs binding to different IL-2R-
binding sites of IL-2 [6,9]: association of IL-2 with S4B6 sterically impedes binding to CD25 by
covering IL-2's CD25 epitope, thus biasing IL-2/S4B6 complexes to preferentially stimulate
CD122high cells, including memory CD8+ T and NK cells; conversely, complexing IL-2 with
JES6-1 occludes IL-2's CD122 and/or gc epitope, thus rendering IL-2 dependent on contact
with CD25 and directing IL-2/JES6-1 complexes to selectively stimulate CD25high cells, such as
Treg cells.
Recent structural data not only provide evidence for the steric aspects of the abovementioned
model but also suggest mild antagonistic and allosteric forces at work (Figure 3). Thus, the data
show that S4B6 covers CD25-interacting epitopes on IL-2, particularly those that lie on helices B
and C of IL-2, which harbor some of the residues important for CD25 binding (Figure 1).
However, S4B6 does not appear to contact the mouse counterparts of hIL-2 residues K35 and
R38 (cf. mIL-2/S4B6 complex structure accessed at accession code PDB: 4YUE [13]). Both
K35 and R38 have previously been shown to be intimately involved in the association of hIL-2
with human CD25 (Figure 1), with R38 representing the residue with the largest estimated buried
surface with CD25 and most numerous van der Waals and hydrogen-bond contacts with CD25
[72]. Hence, these data suggest that S4B6's footprint on IL-2 does not fully overlap with that of
CD25.
Moreover, S4B6 affected the binding of IL-2 to its receptor in two additional ways. Firstly, based
on structural comparison of the mIL-2/S4B6 complex with unbound hIL-2 and hIL-2 in complex
with human CD25, S4B6 binding caused mIL-2 to undergo a slight conformational change in its
helix C leading to increased afﬁnity to CD122 [13], similar to what has been reported for human
CD25-bound IL-2 [8]. Evidence for the relevance of this conformational change comes from the
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study of H9 and D10 hIL-2 muteins (also termed IL-2 ‘superkines’; see next section), which
structurally replicated the said change in helix C and showed 200-fold increased afﬁnities to
CD122, led to more STAT5 phosphorylation in CD25 YT-1 human NK cells, and enhanced
proliferation of human naive CD4+ T cells in vitro [51]. In line with this hypothesis, immobilized
monovalent mIL-2/S4B6 complex showed six-times-higher afﬁnity to monomeric mouse CD122
compared with immobilized mIL-2 [13], which, however, is considerably lower than the binding
afﬁnity to CD122 of the IL-2 superkines [51]. Furthermore, the authors reported a small steric
clash between S4B6 and CD122, presumably antagonizing, at least in part, the afﬁnity-enhanc-
ing effects described above [13]. Nevertheless, the net result of these somewhat opposing
effects was increased binding of IL-2/S4B6 to CD122; however, surprisingly, this did not
translate into enhanced STAT5 phosphorylation [13] or T cell proliferation in vitro [9], which
is unlike the case of IL-2 superkines.
Based on the recent crystal structure of the IL-2/JES6-1 complex, steric effects at the interfaces
of IL-2 with CD122/gc and with CD25, as well as allosteric effects affecting IL-2's CD25-binding
site, have been put forward [13]. The data demonstrated that hydrogen bond contacts existed
between mIL-2 residues Q36 and E37 (corresponding to hIL-2 residues Q22 and M23; Figure 1)
and JES6-1 [13], thereby causing steric competition between JES6-1 and CD122 and gc,
respectively. While these aspects of the structure conﬁrm the previously postulated model, the
proposed steric competition between JES6-1 and CD25 and allosteric changes in IL-2's CD25
epitope are both unexpected and somewhat counterintuitive, considering that IL-2/JES6-1
complexes preferentially stimulate CD25+ cells. Thus, the authors reported that JES6-1 dis-
torted the entire CD25-binding AB loop of mIL-2 by contacting mIL-2 residues K49 and R52,
which in hIL-2 correspond to residues K35 and R38, which are central to CD25 interaction. This
latter ﬁnding makes it difﬁcult to understand how IL-2/JES6-1 complexes are still able to bind to
and stimulate CD25+ cells, especially considering the low-afﬁnity interaction of IL-2 with CD25
compared with the estimated 10–100-fold higher afﬁnity of JES6-1 to IL-2. However, the authors
offered a model whereby, in cells with very high CD25 expression levels, CD25 displaces JES6-1
from IL-2 by mass action, thus liberating IL-2 to engage CD122/gc. This effect is further
enhanced by a positive feedback loop involving IL-2 signaling-mediated transcriptional upre-
gulation of CD25 on responding cells [6,13,73] (cf. also Figure 2).
Collectively, the recent structural data conﬁrm the steric aspects of the proposed model and
further suggest allosteric effects that, especially in IL-2/S4B6 complexes, appear to ﬁne-tune the
mechanistic steps of action of IL-2/mAb complexes, which allows the formulation of a framework
for achieving selective IL-2 immunotherapy (discussed in more detail in the Concluding
Remarks). In addition to IL-2/mAb complexes, studies on selective IL-2 muteins lend support
for such a model, as outlined below.
IL-2 Muteins
An alternative approach to selective IL-2-mediated stimulation is the generation of IL-2 muteins.
Initially, research in this area was driven by the search for IL-2 muteins with reduced toxic
adverse effects. At that time, IL-2-induced toxic effects were thought to rely primarily on
activated NK cells secreting proinﬂammatory cytokines, such as tumor necrosis factor-/,
and vasoactive mediators, which in turn led to endothelial damage and VLS [69]. To this
end, IL-2 muteins were generated with decreased binding afﬁnity to CD122, such as BAY
50-4798 (containing an N88R mutation of IL-2; see also Figure 1) and Selectikine (harboring a
D20T mutation of IL-2) [74,75]. However, when tested in clinical trials such IL-2 muteins did not
show decreased toxicity in patients [10,76]. More recent data showed that NK cells are
implicated in VLS; however, the more proximal events of endothelial cell damage and VLS
include the direct binding of IL-2 to CD25+ pulmonary endothelial cells [31]. Thus, use of IL-2/
S4B6 complexes or of the IL-2 muteins R38E, R38G, R38W, and F42A (all predicted or shown
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to impair binding to CD25) disfavors contact with endothelial cells and signiﬁcantly reduces VLS
[10,31,77].
Capitalizing on these ﬁndings, more recent efforts aimed at generating IL-2 muteins with
decreased afﬁnity to CD25 (such as ‘no-/ mutein’ [78], GA501, and GA504 [79]). An alternative
approach was taken based on the structural data of hIL-2 bound to CD25 [72] and the human
quaternary IL-2–IL-2R complex [8], which suggested that binding to CD25 led to the
CD122-directed
CD8+ memory T cell
CD25: –
CD122 CD25
CD122: +++
γc: present
CD4+ Treg cell
CD122: +
CD25: +++
γc: present
γc
IL-2/S4B6 complex: anbody binds
within IL-2′s CD25 epitope
CD25-directed
IL-2/JES6-1 complex: anbody interacts
with IL-2′s CD122/γc epitopes
Figure 4. Framework for IL-2-Based Selective Immune Modulation, as Exempliﬁed by IL-2/mAb Complexes.
Selective immune modulation – that is, immune stimulation versus immune suppression – can be achieved using IL-2 that
has been modiﬁed to (temporarily) impede IL-2's binding to certain IL-2R subunits. For example, in IL-2/S4B6 complexes
(blue) the anti-IL-2 antibody binds to IL-2's CD25-binding epitope, thereby rendering IL-2 ‘blind’ to CD25. For this and other
reasons (see text), IL-2/S4B6 complexes preferentially stimulate cells expressing high levels of CD122 (in addition to gc,
which in this model is assumed to be not limiting), including memory CD8+ T cells (green) and natural killer cells (not shown).
CD4+ regulatory T (Treg) cells (brown) express only intermediate levels of CD122, which is one of the reasons (see text) why
IL-2/S4B6 complexes are less efﬁcient in activating Treg cells. Conversely, in IL-2/JES6-1 complexes (red), the anti-IL-2
antibody interacts with IL-2's CD122 and gc epitopes. As a consequence IL-2/JES6-1 complexes crucially depend on the
presence of high levels of CD25, such as in CD25+ Treg cells.
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aforementioned structural change of helix C of IL-2 that improved its binding to CD122. Based
on this hypothesis, the agonistic IL-2 muteins H9 and D10 (also known as IL-2 superkines) were
generated [51]. These IL-2 muteins associated with CD122 with 200-fold increased afﬁnity and
efﬁciently bound dimeric IL-2Rs without the need for CD25; such binding resulted in increased
STAT5 phosphorylation and cell proliferation in vitro and in vivo [51]. Use of the H9 IL-2 mutein
showed increased CD8+ T cell-mediated antitumor activity against solid murine tumors [51] and
enhanced NK cell-mediated cytotoxicity against MHC class I-deﬁcient RMA-S tumor cells in vivo
[80].
Leveraging on the properties of H9, an H9 mutant that retained CD122 binding but demon-
strated signiﬁcantly decreased afﬁnity to gc was engineered and characterized recently [14]. This
was achieved by introducing four mutations into H9 (L18R, Q22E, Q126T, and S130R) and the
resultant mutein was called H9-RETR. These newly introduced mutations of H9-RETR affect IL-
2 residues involved in binding to gc (Figure 1). Interestingly, L18 and Q22 are interspaced by two
residues, L19 and D20, that participate in CD122 binding, as shown by structural data [8] or the
D20T IL-2 mutein Selectikine displaying reduced CD122 binding [75]; however, an H9-RE
mutein containing only L18R and Q22E mutations did not show decreased signaling activity
compared with H9 [14]. When used in vivo, an injection of H9-RETR–Fc4 (i.e., H9-RETR fused to
human IgG4 Fc domain) was able to block IL-2- or IL-15-induced STAT5 phosphorylation of
murine CD4+ CD25+ Foxp3+ Treg cells. Moreover, a 10-day course of H9-RETR–Fc4 prevented
acute graft-versus-host disease in a full MHC-mismatch C57BL/6 to BALB/c situation, pre-
sumably by blocking the IL-2R-mediated stimulation of activated effector T cells. In vitro, H9-
RETR was of comparable efﬁcacy to daclizumab, an antihuman CD25 mAb, in inhibiting the
proliferation of adult T cell leukemia cells.
Hence, engineered IL-2 muteins provide interesting tools in being able to either enhance or
dampen IL-2-mediated responses and might be useful for IL-2-directed immune modulation.
Concluding Remarks
Taken together, the ﬁndings on IL-2/mAb complexes and IL-2 muteins suggest a mechanistic
framework for IL-2-based selective immunotherapy, as exempliﬁed by the two functionally
different IL-2/mAb complexes (Figure 4). This concept hinges on the use of qualitatively different
IL-2 variants, namely CD122-biased versus CD25-directed IL-2 formulations, rather than
different IL-2 doses, such as high- versus low-dose IL-2 immunotherapy. IL-2/mAb complexes
have served as a paradigm for IL-2-based selective immune modulation. But how accurate is our
mechanistic understanding of IL-2/mAb complexes?
A mechanistic model of IL-2/mAb complexes, including the new elements arising from the recent
biophysical and structural data, needs to consider the following aspects [6,9,13]: (i) IL-2/mAb
complexes comprise in vitro ‘neutralizing’ anti-IL-2 mAbs; (ii) S4B6 and JES6-1 occupy different
IL-2 sites; (iii) IL-2/S4B6 complexes are CD122 dependent; (iv) IL-2/JES6-1 complexes strictly
depend on CD25; (v) S4B6 partly covers the CD25 epitope; (vi) JES6-1 occupies CD122/gc-
binding sites; (vii) S4B6 shows a mild clash with CD122; (viii) JES6-1 occupies CD122/gc-binding
sites; (ix) S4B6 induces allosteric changes in the CD122 epitope; and (x) JES6-1 allosterically
changes the CD25 epitope of IL-2. In integrating these aspects (Figure 4), it can be proposed
that association of IL-2 with S4B6 (or S4B6-like mAbs) sterically hinders the binding of CD25 to
IL-2 by covering (part of) the CD25-binding site of IL-2 [thus explaining abovementioned points (i)
and (v)], which renders IL-2 ‘blind’ to CD25 but dependent on CD122 [point (iii)]. Of note, maybe
partial – rather than full – obstruction of the CD25 epitope by S4B6-like mAbs is important for
their mechanism of action? Conversely, binding of IL-2 to JES6-1 (or JES6-1-like mAbs)
occludes IL-2 residues interacting with CD122 and/or gc [explaining points (ii) and (vi)]; this
renders IL-2 dependent on CD25 [point (iv)] and inaccessible to CD122 and/or gc until the IL-2/
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JES6-1 complex binds to CD25 thus releasing IL-2 from JES6-1 and making it now amenable to
CD122 and gc.
The proposed allosteric effects in both complexes and the suggested clash between S4B6 and
CD122 [13], however, suggest antagonistic forces at work. Moreover, the apparently discordant
effects seen in IL-2/S4B6 complexes with increased CD122-binding afﬁnity but decreased
STAT5 phosphorylation and reduced T cell proliferation in vitro would suggest further complexity
of the system. These aspects require future studies of IL-2 versus IL-2/mAb complexes focusing
on the binding kinetics of IL-2 to its receptor subunits, internalization and degradation versus
recycling of the IL-2–IL-2R complex, and qualitative and quantitative (i.e., signal duration)
assessment of signaling events. Physiologically, binding of IL-2 to the IL-2R and internalization
of this quaternary complex leads to the degradation of IL-2, CD122, and gc, while CD25 is
recycled [21]. The question arises of whether, in IL-2/mAb complexes, the mAb detaches from
IL-2, whether the mAb is internalized or not, and, if the mAb is internalized, whether it is recycled
to the cell surface or degraded intracellularly. The former point on dissociation and internalization
of the mAb has also practical consequences on whether IL-2/mAb complexes can be devised as
single-molecule fusion proteins. Notably, for clinical application, there is some interest in
generating a fusion protein of IL-2 complex by using a ﬂexible linker between IL-2 and the
mAb, although others do not see a problem with using IL-2/mAb complexes that can dissociate
in vivo (Box 1) [10]. Currently, there is only one report describing a fusion protein of the IL-2/S4B6
complex; however, it remains to be tested to what extent this fusion protein still allows
association of mIL-2 with S4B6's antigen-binding groove [81]. Notably, it is worth considering
the use of S4B6-like mAbs to modulate endogenous IL-2 for selective immune stimulation, as
shown in mice [9]; whether similar effects can be achieved with JES6-1-like mAbs remains to be
explored.
Similar questions apply to CD25- versus CD122-biased IL-2 muteins, which do or do not
require contact with CD25 or CD122/gc. Signiﬁcantly, a particular issue relevant to IL-2 muteins
might be immunogenicity and the generation of antidrug antibodies (see Box 1 for a detailed
discussion).
Box 1. Limitations and Immunogenicity of IL-2 Formulations
Immunotherapy using IL-2 suffers from certain shortcomings [6,69]. First, IL-2 exerts both immunosuppressive and
immunostimulatory actions by activating Treg cells and cytotoxic effector lymphocytes, including CD8+ T cells and NK
cells. Both IL-2/mAb complexes and IL-2 muteins overcome this issue by interfering with interaction of IL-2R subunits
with their respective IL-2 epitopes. Second, high doses of IL-2 can lead to VLS via direct binding of IL-2 to and damage of
CD25+ endothelial cells and indirect damage of endothelial cells by NK cell-derived proinﬂammatory cytokines and
vasoactive mediators. This shortcoming is addressed by the lower doses needed of IL-2/mAb complexes and some IL-2
muteins to achieve the same effects as ‘wild-type’ IL-2 and, in CD122-biased formulations, by avoiding contact with
CD25+ pulmonary endothelial cells. Third, IL-2 is short lived in vivo due to its rapid renal clearance, thus necessitating
frequent administration. Hence, formulations with longer T½ should be generated by coupling, or complexing, IL-2 to a
mAb (or mAb fragment) speciﬁc for IL-2 or a molecule (such as a tumor antigen) enriched in the target tissue [83].
There also exist limitations that are speciﬁc to IL-2/mAb complexes or IL-2 muteins. In IL-2/mAb complexes, the
administration of IL-2 plus an anti-IL-2 mAb could be seen as potentially problematic for therapeutic application as the
two components, although complexed before injection, might dissociate in the patient. This should consider the
following. Even if all IL-2/mAb complexes were to dissociate following injection, the amount of IL-2 would reach only
2–5% of the IL-2 dose usually administered to patients; moreover, the anti-IL-2 mAb could then bind to endogenous IL-2
and direct it to the targeted immune cells. Potentially, IL-2/mAb complexes could be linked by a ﬂexible linker [10,81].
With regard to IL-2 muteins, immunogenicity should be considered. Drug immunogenicity is a well-known problem of
biological agents [84], including IL-2. Both subcutaneous and intravenous administration of recombinant hIL-2 has been
reported to cause anti-IL-2 antibodies in about 50% of patients; however, neutralizing anti-IL-2 antibodies were seen
typically only in 5–10% of subjects treated [85–87]. However, the N88R IL-2 mutein BAY 50-4798 had already caused
antidrug antibodies in 27% of treated patients after two cycles of intravenous infusion [76]. Hence, it is worth considering
strategies to reduce the immunogenicity of IL-2 muteins; for example, by avoiding the formation of aggregates due to
hydrophobicity and lack of glycosylation [85,87].
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When aiming for pure CD25- versus CD122-directed IL-2 formulations, one should consider
possible antagonistic interactions such as those suggested by the structural data on IL-2/mAb
complexes. Notably, the structural data suggest that S4B6 is probably a suboptimal template for
an ideal agonistic IL-2/mAb complex, suggesting that S4B6 partly overlaps with CD25's
footprint on IL-2 and interferes mildly with CD122 binding. These features would both be
unwanted when considering the design of a CD122-directing, high-afﬁnity mimic of CD25
aimed at exerting maximal stimulation of CD8+ T cells while simultaneously blocking IL-2
interaction with CD25+ cells. There, one of the most important challenges will be the setup
of a screening system that allows the selection of appropriate anti-IL-2 mAbs (see Outstanding
Questions). Furthermore, future structural studies on IL-2/mAb complexes should ideally use
S4B6-like hIL-2/mAb complexes tested on human cells and compared with the quaternary IL-2–
IL-2R complex of the same species.
In conclusion, the study of selective IL-2 formulations has been instrumental in understanding
some of the biology of IL-2 and has allowed us dissect the two apparently antagonistic effects of
IL-2. This latter ﬁnding is perhaps the most important consequence of this research and has led
to a conceptual framework for IL-2-based selective immune modulation.
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